Immobazyme, a South African biotechnology spin-out company from Stellenbosch University, has secured $2,900,000 in investment capital from investors. This significant funding round marks a pivotal moment for the company as it progresses its mission within the precision fermentation sector.
The company specialises in utilising precision fermentation to produce high-value active protein ingredients. Immobazyme's core objective is to catalyse the future of global innovation by creating desirable and accessible recombinant proteins. This approach aims to enable businesses across various sectors to refine their products and unlock the full potential of their process development. Immobazyme is also ISO 9001:2015 certified, reflecting its commitment to quality and operational excellence.
The newly raised capital will be instrumental in supporting Immobazyme’s strategic growth initiatives. The company plans to use the funds to expand its operational capabilities, scale up its production processes, and further invest in research and development to enhance its technology platform. This investment underscores investor confidence in Immobazyme's innovative approach and its potential to deliver critical ingredients to the global market.
This funding round is expected to accelerate Immobazyme's trajectory, allowing it to increase its market reach and solidify its position as a key player in the biotechnology landscape. The company remains dedicated to advancing precision fermentation technology and expanding its portfolio of high-value protein solutions, contributing to more efficient and sustainable industrial applications.
